Gunnar Nordvall

Huddinge, AB, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Analgesic, anti-inflammatory and joint protective effects of ACD137, a selective negative allosteric modulator of TrkA, in models of chemotherapy-induced peripheral neuropathy and osteoarthritis.

Analgesic, anti-inflammatory and joint protective effects of ACD137, a selective negative allosteric modulator of TrkA, in models of chemotherapy-induced peripheral neuropathy and osteoarthritis.

Journal: Scandinavian journal of pain
Published: November 28, 2025

Response to the Letter to the Editor on "γ-Secretase modulation and plaque regression in Alzheimer's disease".

Response to the Letter to the Editor on "γ-Secretase modulation and plaque regression in Alzheimer's disease".

Journal: The Journal of pharmacology and experimental therapeutics
Published: August 12, 2025

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.

Journal: Cells
Published: April 04, 2025

Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand.

Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand.

Journal: ACS chemical neuroscience
Published: November 11, 2024

γ-Secretase modulation inhibits amyloid plaque formation and growth and stimulates plaque regression in amyloid precursor protein/presenilin-1 mice.

γ-Secretase modulation inhibits amyloid plaque formation and growth and stimulates plaque regression in amyloid precursor protein/presenilin-1 mice.

Journal: The Journal of pharmacology and experimental therapeutics
Published: September 27, 2024

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 17, 2024

Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease.

Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease.

Journal: Frontiers in molecular neuroscience
Published: August 18, 2023

Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.

Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.

Journal: International journal of molecular sciences
Published: May 30, 2023

Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?

Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?

Journal: Psychopharmacology
Published: July 05, 2022

Neurotrophin-targeted therapeutics: A gateway to cognition and more?

Neurotrophin-targeted therapeutics: A gateway to cognition and more?

Journal: Drug discovery today
Published: May 31, 2022

Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction.

Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction.

Journal: Cells
Published: June 22, 2021

γ-Secretase modulators show selectivity for γ-secretase-mediated amyloid precursor protein intramembrane processing.

γ-Secretase modulators show selectivity for γ-secretase-mediated amyloid precursor protein intramembrane processing.

Journal: Journal of cellular and molecular medicine
Published: September 17, 2020
Showing 1-12 of 19

Last Updated: 09/26/2026